

**Supplementary Table 3.** Clinical parameters at baseline and the changes that occurred from baseline (SWITCH vs. fibrate-treated control)

Variable	SWITCH (n=96)	Mean change at 52 weeks (95% CI)	Control (fibrate-treated) (n=75)	Mean change at 52 weeks (95% CI)	P value
eGFR, mL/min/1.73 m <sup>2</sup>	67.4±18.7	7.9 (5.8 to 10.1) <sup>c</sup>	68.1±19.5	-0.3 (-2.7 to 2.0)	<0.0001
BMI, kg/m <sup>2</sup>	27.1±3.6	-0.22 (-0.41 to -0.03) <sup>a</sup>	27.0±4.0	-0.17 (-0.33 to -0.02)	0.6945
TC, mg/dL	180.0±26.7	-1.1 (-5.1 to 2.9)	180.4±33.6	-3.0 (-8.1 to 2.0)	0.5484
TG, mg/dL	145 (120–191)	-14 (-135 to 41) <sup>c</sup>	138 (101–179)	0 (-57 to 97)	0.0227
HDL-C, mg/dL	50.7±12.8	0.7 (-1.3 to 2.7)	53.4±13.3	-1.5 (-3.1 to 0.0)	0.0968
FPG, mg/dL	132.4±22.7	2.9 (-1.8 to 7.6)	132.9±29.4	2.7 (-2.3 to 7.6)	0.9428
HbA1c, %	7.1±0.7	0.12 (-0.01 to 0.25)	7.0±0.7	0.05 (-0.09 to 0.18)	0.4127
AST, IU/L	27 (21–38)	-3 (-31 to 15) <sup>c</sup>	25 (19–37)	0 (-31 to 18)	0.0003
ALT, IU/L	29 (19–42)	-5 (-45 to 17) <sup>c</sup>	24 (15–37)	0 (-30 to 20)	<0.0001
γ-GTP, IU/L	34 (22–49)	-3 (-48 to 21) <sup>b</sup>	31 (19–53)	0 (-38 to 46)	0.0409
UA, mg/dL	5.0±1.5	1.09 (0.87 to 1.32) <sup>c</sup>	5.2±1.4	0.12 (-0.10 to 0.34)	<0.0001

Values are presented as mean ± standard deviation, median (interquartile range), or mean change (95% CI). The significance of differences in the changes from baseline to 52 weeks between the ADD-ON group and control group was examined using an unpaired *t*-test or the Mann-Whitney *U* test.

CI, confidence interval; eGFR, estimated glomerular filtration rate; BMI, body mass index; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; UA, uric acid.

<sup>a</sup>*P*<0.05, <sup>b</sup>*P*<0.01, <sup>c</sup>*P*<0.001 vs. each baseline.